Acclinate Wins DPHARM Idol Disrupt 2022 Presented at 12th Annual DPHARM from the Conference Forum

By

[BOSTON, Sept. 14, 2022  /PRNewswire-PRWeb/] The Conference Forum is pleased to announce that Acclinate is the winner of DPHARM Idol Disrupt at the 12th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2022 event.

Acclinate, represented by Del Smith, PhD, CEO and Co-Founder, specializes in accessing and engaging communities of color to enhance clinical trial diversity, helping pharmaceutical companies enhance diversity through access to an already established online community, not through cold outreach to potential participants.

“The recent FDA draft guidances for diversity plans, as well as independent initiatives from pharmaceutical companies, makes Acclinate’s work both timely and relevant,” said Doug Schantz, SVP, Clinical Operations, Asklepios BioPharm and DPHARM Idol Disrupt JudgePost this

Acclinate had six minutes to present to DPHARM Idol Disrupt’s judges, followed by a rigorous Q&A.

“The core of what Acclinate is addressing is increasing trust, particularly with communities of color,” said Dr Smith. “It is about engaging with the individual before they become a patient, going further upstream in the process to do the work necessary to build trust.”

The DPHARM Idol Disrupt judges appreciated the combination of external community outreach and technology support, to develop a participation probability index through Acclinate’s community platform NOWINCLUDED and clinical trial management system e-DICT.

“The recent FDA draft guidances for diversity plans, as well as independent initiatives from pharmaceutical companies, makes Acclinate’s work both timely and relevant,” said Doug Schantz, SVP, Clinical Operations, Asklepios BioPharm and DPHARM Idol Disrupt Judge.

Acclinate had strong competition from the other DPHARM Idol Disrupt contenders:

  • Autonomize – Represented by Ganesh Padmanabhan, MBA, CEO and Founder
  • Captario – Represented by Matthew Kokkonen, MBA, Director, Strategic Account Management
  • Cognivia – Represented by Dominique Demolle, CEO
  • Seqster – Represented by Ardy Arianpour, CEO & Founder
  • Trialbee – Represented by Matt Walz, CEO

“The focus at DPHARM Idol Disrupt is not just on the ‘wow factor’ but on picking a company that represents a disruption that has potential to soon make a meaningful difference for patients. Acclinate provides something that can be broadly implemented, accessible to most people and provides a high-value solution,” said Cindy Geoghegan, Patient Advocate and long-time Idol judge.

The judges included:
David Apfel, Head, Data Science External Innovation, Janssen Research & Development LLC
Cindy Geoghegan, Patient Advocate
Yusuf Ghadiali, Executive Director, Head of Clinical Trial Operations, Daiichi Sankyo
Andrea Jackson, Director, Northpond Ventures
Hassan Kadhim, Director, Head of Clinical Trial Business Capabilities, Global Development Operations, BMS
Sarah Krüg, Executive Director, Cancer101/CEO, Health Collaboratory
Matt W. Maddox, AVP, Eli Lilly and Company
Judith Reece, PhD, VP, Digital Development, GSK
Doug Schantz, SVP, Clinical Operations, Asklepios BioPharm
Merle Schneider, Senior Director, Monitoring Excellence, Global Clinical Trials Operations, Merck & Co. Inc.
Donna Usiskin, Chief Strategy Officer, New Enterprise Ventures
Taylor Uttley, Head of Strategy and Operations, Data Strategy and Solutions, Vertex Pharmaceuticals

For more information, please contact service@tcfllc.org or visit theconferenceforum.org.

About DPHARM:
DPHARM® is an established conference going into its 12th year. It offers an unparalleled opportunity to hear senior clinical operation executives and innovative thought leaders
unveil the latest innovations to modernize clinical trials and reduce patient burden. The concept of DPHARM was founded by Pfizer and Janssen, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program.

About The Conference Forum:
The Conference Forum is a life science industry research firm that brings key people together to share and exchange ideas and information on how to get therapeutics to patients faster. We continue to examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common, patient-centered goals. Each of our key research areas – Clinical Trial Innovation, Patients as Partners, R&D Leadership, Immuno-Oncology, Drug Delivery and Clinical Research as a Care Option – has a dedicated conference, quarterly newsletter and podcasts.

Media Contact

Allyson Adams, Conference Forum, 6462906797, allyson@tcfllc.org

Last modified: December 3, 2023